What is the official ID of this bill?
The official print number for this legislation is HR 1350.
Support for Rare Disease Treatment: Tax Credits and Research
This law aims to improve access to rare disease medications by increasing tax credits for companies that produce them. Additionally, it mandates the Centers for Disease Control and Prevention (CDC) to study how to better track and collect data on rare diseases, which could aid in their diagnosis and treatment. Citizens may benefit from potentially greater availability and development of rare disease drugs.
Key points
Increases the tax credit for companies developing orphan drugs from 25% to 50%, potentially encouraging more research and production.
Requires the CDC to conduct a feasibility study on enhancing infrastructure for tracking rare diseases, aiming for better understanding and management.
The CDC study will cover mortality rates, treatment potential, demographics, and disease progression, crucial for addressing rare conditions.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.